Citius Oncology, Inc.
Citius Oncology’s Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma
Presented at Premier Global CLTG Congress in Europe
Company newsroom
Citius Oncology, Inc.
NASDAQ:CTOR · NASDAQ:CTXR
1 releases